title: A platform for controlled dual-drug delivery to the retina: protective effects against light-induced retinal damage in rats.
abstract: Controlled transscleral co-delivery of two drugs, edaravone (EDV) and unoprostone (UNO), using a platform that comprises a microfabricated reservoir, controlled-release cover, and drug formulations, which are made of photopolymerized poly(ethyleneglycol) dimethacrylates, shows synergistic retinal neuroprotection against light injury in rats when compared with single-drug-loaded devices. The device would offer a safer therapeutic method than intravitreal injections for retinal disease treatments.
authors.affiliation: Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Nagai
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Kaji
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Onami
authors.forename: Yuki
authors.initials: Y
authors.lastname: Katsukura
authors.forename: Yumi
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Zhaleh Kashkouli
authors.initials: ZK
authors.lastname: Nezhad
authors.forename: Kaori
authors.initials: K
authors.lastname: Sampei
authors.forename: Satoru
authors.initials: S
authors.lastname: Iwata
authors.forename: Shuntaro
authors.initials: S
authors.lastname: Ito
authors.forename: Matsuhiko
authors.initials: M
authors.lastname: Nishizawa
authors.forename: Toru
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Noriko
authors.initials: N
authors.lastname: Osumi
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Mashima
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Abe
mesh_terms: D060433:Administration, Ophthalmic; D000818:Animals; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D015237:Dinoprost / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004338:Drug Combinations; D016503:Drug Delivery Systems / Q000295:instrumentation* / Q000379:methods*; D000077553:Edaravone; D004867:Equipment Design; D008689:Methacrylates / Q000737:chemistry; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D011092:Polyethylene Glycols / Q000737:chemistry; D011109:Polymethacrylic Acids / Q000737:chemistry; D019736:Prostheses and Implants; D051381:Rats; D012160:Retina / Q000378:metabolism* / Q000528:radiation effects; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D012590:Sclera / Q000601:surgery
chemical_list: D004338:Drug Combinations; D008689:Methacrylates; D018696:Neuroprotective Agents; D011109:Polymethacrylic Acids; C421283:poly(ethylene glycol)-dimethacrylate; C020946:triethylene glycol dimethacrylate; D011092:Polyethylene Glycols; C072630:isopropyl unoprostone; D015237:Dinoprost; D000077553:Edaravone; D000983:Antipyrine
keywords: edaravone; poly(ethyleneglycol) dimethacrylate; retina; transscleral drug delivery; unoprostone